Last edited by Mitaxe
Friday, November 27, 2020 | History

4 edition of Cancer drug resistance found in the catalog.

Cancer drug resistance

proceedings of a workshop held at the XIV International Congress of Chemotherapy in Kyoto, Japan, June 23-28, 1985

by

  • 104 Want to read
  • 15 Currently reading

Published by Liss in New York .
Written in English

    Subjects:
  • Drug resistance in cancer cells -- Congresses.,
  • Antineoplastic Agents -- pharmacodynamics -- congresses.,
  • Drug Resistance -- congresses.,
  • Neoplasms -- drug therapy -- congresses.

  • Edition Notes

    Statementeditor, Thomas C. Hall.
    SeriesProgress in clinical and biological research ;, v. 223
    ContributionsHall, Thomas C., 1921-, International Congress of Chemotherapy (14th : 1985 : Kyoto, Japan)
    Classifications
    LC ClassificationsRC271.C5 C3223 1986
    The Physical Object
    Paginationxviii, 235 p. :
    Number of Pages235
    ID Numbers
    Open LibraryOL2727027M
    ISBN 100845150731
    LC Control Number86020867

    17 hours ago  VERU for Metastatic Castration and Androgen Receptor Targeting Agent Resistant Prostate Cancer. VERU is an oral, first-in-class, new .


Share this book
You might also like
life and genius of Lord Byron

life and genius of Lord Byron

It seems like yesterday

It seems like yesterday

Developing or controlling creative thinking

Developing or controlling creative thinking

influence of personality factors on postoperative pain, anxiety and analgesic requirements following elective lower abdominal surgery

influence of personality factors on postoperative pain, anxiety and analgesic requirements following elective lower abdominal surgery

Headed for Eden

Headed for Eden

English first editions of Hilaire Belloc

English first editions of Hilaire Belloc

The three Rs of the eighties

The three Rs of the eighties

A secret history of time to come

A secret history of time to come

Murderers!

Murderers!

Echinoderm faunas of the Hongguleleng Formation, late Devonian (Famennian), Xinjiang-Uygur Autonomous Region, Peoples Republic of China

Echinoderm faunas of the Hongguleleng Formation, late Devonian (Famennian), Xinjiang-Uygur Autonomous Region, Peoples Republic of China

Dark blood

Dark blood

goodness of God ... displayed: in a sermon preached at the Merchants lecture in Salters-hall ... 1723.

goodness of God ... displayed: in a sermon preached at the Merchants lecture in Salters-hall ... 1723.

Responsibility

Responsibility

Watercolours

Watercolours

Cancer drug resistance Download PDF EPUB FB2

In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities.

The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR).

Reviewed in the United States on April 3, This an extremely sophisticated analysis of one of the most troubling aspects of chemotherapy, namely the tendency over time for a patient to develop resistance to the agent being applied.

The Goldie-Coldman model for resistance is one of the best known in chemotherapy.5/5(1). Authoritative and insightful, Cancer Drug Resistance offers basic and clinical investigators a state-of-the-art synthesis of the many faceted research now available on the biology and genetics of tumor resistance, as well as exciting new approaches to its prevention and eradication.

This volume discusses the latest advancements and technologies used in cancer drug resistance research. Cancer Drug Resistance: Overviews and Methods contains chapters that cover topics such as: studying the mechanics of resistance to DNA damaging therapeutic drugs; studies to delineate Cancer drug resistance book role of efflux transporters; expression of drug transporters; resistance to targeted therapies in breast.

Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, Cancer drug resistance book mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

The book, while quite comprehensive, is not designed to, nor does it attempt to cover the entire field of drug resistance. The focus of the book is to highlight specific mechanisms of cancer drug resistance and review or propose new treatments targeting each of these mechanisms.

Cancer Drug Resistance: Unraveling Its Complexity. On This Page. Targeting Cancer Cell Plasticity. Treating Cancers Like Evolving Ecosystems.

Degrading—Not Blocking—the Target to Avoid Resistance. Using Advanced Preclinical Models to Address Resistance. It’s a heartbreaking story, and one that happens too often. Cancer Drug Resistance is a quarterly published journal committed to the rapid publication of high quality, peer-reviewed, original research.

The subject of drug resistance in cancer is very broad, and many different scenarios are possible. For example, a targeted drug may not be directly killing cancerous cells but instead, it can selectively affect tumor-derived endothelial cells.

This is the basic principle of antiangiogenic Cancer drug resistance book. There, a different mechanism of resistance is possible, when hypoxia (which is a consequence of the therapy) selects for vessel-independent (and therefore resistant) cancer.

Authoritative and insightful, Cancer Drug Resistance offers basic and clinical investigators a state-of-the-art synthesis of the many faceted research now available on the biology and genetics of tumor resistance, as well as exciting new approaches to its prevention and eradication.

--This text refers to the paperback cturer: Humana. Introduction. Cancer is the second leading cause of death in the US [].Inabout million people were diagnosed with cancer and million people died from the disease [].Drug resistance and the resulting ineffectiveness of the drug treatment are responsible for up to 90% of the cancer related deaths [].

Drug resistance in cancer is a well-known phenomenon that results when cancer Cited by: Cancer drug resistance continues to be a major impediment in medical oncology. Clinically, resistance can arise prior to or as a result of cancer therapy.

In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metabolism, mutation and amplification of drug targets, as well as genetic rewiring which can lead to.

Despite the development of targeted therapy, drug resistance remains a primary hindrance to curative treatment of various cancers. Among several novel approaches to overcome drug resistance, modulating N 6 -methyladenosine (m 6 A) RNA modification was found to be an important strategy in various types of cancer cells.

Download Mechanisms Of Drug Resistance In Cancer Therapy full book in PDF, EPUB, and Mobi Format, get it for read on your Kindle device, PC, phones or tablets. Mechanisms Of Drug Resistance In Cancer Therapy full free pdf books.

The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress.

This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug. Cancer therapies are limited by the development of drug resistance, and mutations in drug targets is one of the main reasons for developing acquired resistance.

The adequate knowledge of these mutations in drug targets would help to design effective personalized therapies. Keeping this in. Studies on mechanisms of cancer drug resistance have yielded important information about how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

This book presents new and important research in this field. This review summarizes the current field in terms of the challenges and opportunities that cancer resistance presents to drug discovery scientists, with a focus on small molecule therapeutics.

As part of this review, common themes and approaches have been identified which have been utilized to successfully target emerging mechanisms of resistance. Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.

The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell.

Among the different metabolic and signalling pathways that are altered in cancer cells, variations in the expression and activity of several drug- metabolizing enzymes play a critical role in drug resistance (Rochat, ).

Resistance can occur prior to drug treatment (primary or innate resistance) or may develop over time following exposure to the drug (acquired resistance).Cited by: In an effort to successfully treat breast cancer, it is imperative to a) fully understand the disease with all its heterogeneity, b) understand the factors that influence the metastasis of breast cancer to distant organs making it lethal and c) understand the underlying processes that lead to the phenomenon of drug-resistance making the disease.

Drug resistance accounts for many cancer recurrences and associated deaths. Despite progress in understanding drug resistance over the last decade, knowledge gaps remain about the underlying biological causes of drug resistance and the design of cancer treatments to overcome it. SCO The novel drug targets proteins known to be responsible in resistance to anti-cancer drugs.

It works by inhibiting the SRPK1 kinase and degrading the ABCG2 drug efflux pump. Efflux pumps are present in cells and transport several different drugs to the outside of the cell. Cancer Drug Resistance: Early Studies.

InR.W. Brockman (a former Head of the Drug Resistance Section of the Southern Research Institute) completed an approximately page book chapter describing in detail the knowledge of anticancer drug resistance mechanisms at that by: Commonly known as drug resistance, this phenomenon is one of the most challenging problems facing cancer researchers and patients today.

When cancer cells resist the effects of drugs used for treatment, they can grow and reform tumors, a process known as recurrence or relapse. Sometimes resistance develops quickly, within a matter of weeks of starting treatment. Drug resistance is a major cause of cancer treatment failure.

NCI supports research to overcome this resistance, including basic science to understand biological mechanisms and clinical trials that test new cancer treatment strategies. Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available.

The book discusses reasons why colorectal tumors become refractory during the progression of the. Drug resistance is a major obstacle in the treatment of breast cancer.

Surviving cells lead to tumor recurrence and metastasis, which remains the main cause of cancer-related mortality. Breast cancer is also highly heterogeneous, which hinders the identification of individual cells with the capacity to survive anticancer treatment. These drugs also come from several different families of chemotherapy drugs, so the phenomenon of drug resistance is not confined to one family of cancer drugs or one type of cancer.

In order to combat resistance, chemotherapy drugs are often given in combination in the hopes that the cancer will fail to resist at least one of the drugs in the.

Collectively, these data suggest that ALDH1 expression demonstrates a functional role in breast cancer metastasis and therapy resistance. Thus, drug development that targets ALDH1-expressing tumor cells may represent a novel therapeutic strategy to treat metastatic breast cancer patients in the future.

First line therapy for colorectal cancer (CRC) is usually fluoropyrimidine monotherapy and oxaliplatin, or irinotecan-based therapy. Additionally, targeted therapies such as bevacizumab, aflibercept, ramucirumab, regorafenib, cetuximab and panitumumab are indicated in combination with chemotherapy in metastatic CRC.

Resistance of CRC to treatment is the principal rationale for Cited by: 1. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop Edition: 1.

NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. Antineoplastic resistance, often used interchangeably with chemotherapy resistance, is the resistance of neoplastic (cancerous) cells, or the ability of cancer cells to survive and grow despite anti-cancer therapies.

In some cases, cancers can evolve resistance to multiple drugs, called multiple drug resistance. There are two general causes of antineoplastic therapy failure: Inherent genetic. Lori Hazlehurst, Miles Hacker, in Pharmacology, Summary.

We have discussed examples of drug resistance reported for both cancer cells and infectious diseases. There are myriad ways in which both populations of cells develop drug resistance depending upon the drug type and the cell type.

Those studying drug resistance have noticed a pattern, however: Cell lines made from chemotherapy-treated small-cell lung cancer patients are three or four times more likely to carry extra copies of genes in the Myc family.

These genes are involved in many cellular processes, including growth. Sometimes cancer can become resistant to cancer drug treatment. Cancers develop from normal cells that have changed or mutated to become cancerous.

The mutation happens in the genes of the cell. These gene changes make the cell behave differently to a normal cell. Cancer cells can continue to mutate so that they become more and more abnormal. 1. Introduction. Cisplatin, approved by the Food and Drug Administration inhas high cure rate for many kinds of malignancies, including testicle, ovarian, cervical, head and neck, esophagus, and lung cancer [, ].The cytotoxicity of cisplatin is derived from its ability to inhibit DNA replication through G2/M phase arrest, DNA damage, and activation of apoptotic molecules [4,5].

This comprehensive book on breast cancer brings together some of the leading experts in an attempt to better understand breast cancer disease, the factors that make it lethal and current research progress, integrating both basic research with clinical implications.

drug resistance mechanisms in breast cancer against targeted therapies and v. 4. General Mechanisms of Drug Resistance in CRC. Drug resistance in CRC involves multiple mechanisms, such as the decrease in the delivery of drug to the cancer cells, increase in an efflux out of the cells that are mediated by ATP-dependent transporters, decrease in uptake into the cells, or a change in enzymes that are involved in metabolism [].On the other hand, resistance can be conferred.

Scientists from the Universities of Bristol and Parma, Italy, have used molecular simulations to understand resistance to osimertinib -- an anticancer drug used to treat types of lung cancer.

Multidrug resistance (MDR) -- a process in which tumors become resistant to multiple medicines -- is the main cause of failure of cancer chemotherapy. Tumor cells often acquire MDR by .